Rabbit anti-Human TICAM1 Polyclonal Antibody | anti-TICAM1 antibody

TICAM1 antibody

Cat. Num. AAA9413295

• Gene Names: TICAM1; TRIF; IIAE6; MyD88-3; PRVTIRB; TICAM-1
• Reactivity: Human
• Applications: Western Blot
• Purity: Antibodies were purified by affinity purification using immunogen.
• Synonyms: TICAM1; Polyclonal Antibody; TICAM1 antibody; TRIF; PRVTIRB; TICAM-1; anti-TICAM1 antibody

• Host: Rabbit
• Reactivity: Human
• Clonality: Polyclonal
• Specificity: The antibody detects endogenous level of total TICAM1 antibody.
• Purity/Purification: Antibodies were purified by affinity purification using immunogen.
• Form/Format: Supplied at 1.0mg/mL in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.
• Concentration: 1.0 mg/ml (varies by lot)
• Sequence Length: 712

• Applicable Applications for anti-TICAM1 antibody: Western Blot (WB)
• Application Notes: Western blotting: 1:500 - 1:2000
• Immunogen Type: Recombinant Protein
• Immunogen Description: Recombinant protein of human TICAM1.
• Target Name: TICAM1
• Preparation and Storage: Store at -20 degree C

Western Blot (WB)

(Western blot analysis of lung cell lysate using TICAM1 antibody.)

Related Product Information for anti-TICAM1 antibody

Members of the Toll-like receptor (TLR) family, named for the closely related Toll receptor in Drosophila, play a pivotal role in innate immune responses (1-3). TLRs recognize conserved motifs found in various pathogens and mediate defense responses. Triggering of the TLR pathway leads to the activation of NF-kB and subsequent regulation of immune and inflammatory genes. The TLRs and members of the IL-1 receptor family share a conserved stretch of approximately 200 amino acids known as the TIR domain. Upon activation, TLRs associate with a number of cytoplasmic adaptor proteins containing TIR domains including MyD88 (myeloid differentiation factor), MAL/TIRAP (MyD88-adaptor-like/TIR-associated protein), TRIF (Toll-receptor-associated activator of interferon), and TRAM (Toll-receptor-associated molecule). This association leads to the recruitment and activation of IRAK1 and IRAK4, which form a complex with TRAF6 to activate TAK1 and IKK. Activation of IKK leads to the degradation of IkB that normally maintains NF-kB inactivity by sequestering it in the cytoplasm.

Product Categories/Family for anti-TICAM1 antibody

Total protein Ab

NCBI and Uniprot Product Information

• NCBI GI #: 41281981
• NCBI GeneID: 148022
• NCBI Accession #: NP_891549.1
• NCBI GenBank Nucleotide #: NM_182919.3
• UniProt Accession #: Q8IUC6; O75532; Q86XP8; Q96GA0; B3Y691
• Molecular Weight: 76,422 Da
• NCBI Official Full Name: TIR domain-containing adapter molecule 1
• NCBI Official Synonym Full Names: toll-like receptor adaptor molecule 1
• NCBI Official Symbol: TICAM1
• NCBI Official Synonym Symbols: TRIF; IIAE6; MyD88-3; PRVTIRB; TICAM-1
• NCBI Protein Information: TIR domain-containing adapter molecule 1
• UniProt Protein Name: TIR domain-containing adapter molecule 1
• Protein Family: TIR domain-containing adapter molecule
• UniProt Gene Name: TICAM1
• UniProt Synonym Gene Names: PRVTIRB; TRIF; TICAM-1; MyD88-3; TIR domain-containing adapter protein inducing IFN-beta
• UniProt Entry Name: TCAM1_HUMAN

NCBI Description

This gene encodes an adaptor protein containing a Toll/interleukin-1 receptor (TIR) homology domain, which is an intracellular signaling domain that mediates protein-protein interactions between the Toll-like receptors (TLRs) and signal-transduction components. This protein is involved in native immunity against invading pathogens. It specifically interacts with toll-like receptor 3, but not with other TLRs, and this association mediates dsRNA induction of interferon-beta through activation of nuclear factor kappa-B, during an antiviral immune response. [provided by RefSeq, Jan 2012]

Uniprot Description

TICAM1: an adaptor protein involved in innate immunity against invading pathogens. Associates with TLR3 and TLR4 (through TICAM2) to mediate NF-kappa-B and interferon-regulatory factor (IRF) activation, and to induce apoptosis. Ligand binding to these receptors results in TICAM1 recruitment through its TIR domain. Distinct protein-interaction motifs allow recruitment of the effector proteins TBK1, TRAF6 and RIPK1, which in turn, lead to the activation of transcription factors IRF3 and IRF7, NF-kappa-B and FADD respectively. Interacts with the TIR domain of TLR3. Interacts with AZI2, TBK1, IRF3 and IRF7. Interacts with TICAM2 in TLR4 recruitment. Interaction with PIAS4 inhibits the TICAM1-induced NF-kappa-B, IRF and IFNB1 activation. Interacts with IKBKB and IKBKE. Interaction with SARM1 blocks TICAM1-dependent transcription factor activation. Interacts with TRAF3. Interacts with TRAFD1.

Protein type: Apoptosis; Adaptor/scaffold

Chromosomal Location of Human Ortholog: 19p13.3

Cellular Component: endosome membrane; cytosol

Molecular Function: protein binding; signal transducer activity; protein kinase binding

Biological Process: I-kappaB kinase/NF-kappaB cascade; positive regulation of I-kappaB kinase/NF-kappaB cascade; positive regulation of nitric oxide biosynthetic process; positive regulation of protein binding; regulation of protein homodimerization activity; MyD88-independent toll-like receptor signaling pathway; positive regulation of interleukin-6 production; toll-like receptor 3 signaling pathway; positive regulation of tumor necrosis factor production; positive regulation of natural killer cell activation; activation of NF-kappaB transcription factor; positive regulation of chemokine biosynthetic process; response to exogenous dsRNA; positive regulation of protein ubiquitination; macrophage activation during immune response; positive regulation of interferon-beta biosynthetic process; lipopolysaccharide-mediated signaling pathway; positive regulation of B cell proliferation; toll-like receptor signaling pathway; innate immune response; inflammatory response; toll-like receptor 4 signaling pathway; defense response to virus

Disease: Herpes Simplex Encephalitis, Susceptibility To, 4